(3-trifluoromethoxyphenyl)-(all-trans)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid amide | 1197356-82-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (3-trifluoromethoxyphenyl)-(all-trans)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid amide
• 英文别名: (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-N-[3-(trifluoromethoxy)phenyl]nona-2,4,6,8-tetraenamide
• CAS: 1197356-82-3
• 化学式: C₂₈H₃₀F₃NO₃
• 分子量: 485.546
• InChiKey: LZVFVMFYXLMYFC-QYKWGFQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  6

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  阿维A酸	acitretin	55079-83-9	C21H26O3	326.436
  ——	9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid chloride	74479-50-8	C21H25ClO2	344.881

反应信息

• 作为产物：
  描述：

  阿维A酸 在 吡啶 、 三氯化磷 作用下， 以 甲苯 为溶剂， 反应 7.0h， 生成 (3-trifluoromethoxyphenyl)-(all-trans)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid amide
  参考文献：
  名称：

  Retinoid Derivative and Pharmaceutical Composition and Use Thereof

  摘要：

  这项发明涉及一种视黄醇衍生物及其药物组合物和用途。该发明的化合物能够预防或治疗血液肿瘤，如急性白血病、慢性白血病、多发性骨髓瘤和淋巴瘤，实体肿瘤，如肝癌、直肠癌、乳腺癌和食道癌，以及皮肤疾病，如银屑病和痤疮。

  公开号：

  US20110077298A1

文献信息

• RETINOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Anhui Medical University

  公开号：EP2279999B1

  公开（公告）日：2015-05-27
• USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
  申请人：Fabius Biotechnology

  公开号：US20210338558A1

  公开（公告）日：2021-11-04

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.
• US8110703B2
  申请人：——

  公开号：US8110703B2

  公开（公告）日：2012-02-07
• [EN] USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN<br/>[FR] UTILISATION DE DOMAINES DE LIAISON AU COLLAGÈNE POUR DÉLIVRER DES PRODUITS À LA PEAU
  申请人：FABIUS BIOTECHNOLOGY

  公开号：WO2020068665A1

  公开（公告）日：2020-04-02

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1 ) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.